Tweets
EULAR Classification criteria for hemachromatosis, presented by Prof. Kiely shows clinical pearls in diagnosis - Hook osteophytes @MCP 2/3, & Iron Fist sign w/ elevation of MCPs 2&3. #EULAR2025 https://t.co/ICSDysexOR
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Review of IL-1 family cytokines in inflammation and immunity - including, IL-1, IL-18, IL-33, IL-36, IL-37, IL-38, IL-1Ra, etc. Full read -- Good Reference!! https://t.co/01o05qYPjU https://t.co/M02xrvxKre
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
APP Pearls “Never stop learning—rheumatology is full of surprises” - Kayla Carlucci, FNP-BC
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis
The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/G2SS0qJTfl
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Three Things to Know About Hiring, Onboarding, and Training APPs
As the utilization of APPs (nurse practitioners and physician assistants) in rheumatology becomes more prevalent, here are three things to consider if you are thinking about adding an APP to your practice:
Read https://t.co/24RVd09vcK
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
Telling You Where to Go (12.19.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients? https://t.co/bwF89L9Z7R
Dr. John Cush @RheumNow ( View Tweet )
2 days ago
APP Controversies and Misconceptions
In this Tuesday Night Rheumatology, panelists discuss a range of topics, including APP roles and impact; models of care; independence; seeing new patients and complex cases; and more. Panelists: Daric A. Mueller, PA-C; Lisa Carnago, PhD, https://t.co/t2PssfUNoV
Dr. John Cush @RheumNow ( View Tweet )
3 days ago
APP Pearls “You must assess sleep and mood- without this, even if you control all inflammation, you will not control pain and fatigue!” - Christine Stamatos, NP, DNP, RN
Dr. John Cush @RheumNow ( View Tweet )
3 days ago
Tricks of the Trade – Clinic Advice from APPs
December 2025 is focused on advanced practice providers, their impact, education and priorities. In seeking and soliciting the help and advice of leaders in the rheumatology APP world, I have been impressed by APP pride, dedication https://t.co/boyjytkUyq
Dr. John Cush @RheumNow ( View Tweet )
3 days ago
Hidden in Plain Sight: IBD
As a PA with six years of experience in rheumatology and a background in gastroenterology, today I'm discussing the clinical overlap between inflammatory arthritis—particularly psoriatic arthritis and spondyloarthropathies—and inflammatory bowel https://t.co/Aatc4jkbpH
Dr. John Cush @RheumNow ( View Tweet )
3 days ago
Disease Activity Criteria for Adult-Onset Still's Disease: EULAR Points to Consider
EULAR has published a "points to consider" (PtCs) guidance on the development of criteria for the assessment of the disease activity in adult-onset Still’s disease (AOSD). https://t.co/3FikFiGgxM
Dr. John Cush @RheumNow ( View Tweet )
4 days 1 hour ago
NPs and PAs: Opportunities Outside of the Exam Room
Ben Smith, PA-C, Thomasville, GA, discusses scholarly and leadership opportunities for nurse practitioners and physician assistants, as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/Vzx6B1z2xJ
Dr. John Cush @RheumNow ( View Tweet )
4 days ago


